Gabapentin Market Projected to Reach USD 3.77 Billion by 2034, Expanding at a 5.3% CAGR

The gabapentin market is expected to gain market growth during the forecast period of 2025-2034. Polaris Market Research analyzes the market to account for USD 3,768.43 million by 2034 and is expected to register a CAGR of 5.3% in the above-mentioned forecast period. The market was valued at USD 2,253.78 million in 2024.

Market Overview:
Gabapentin is an anticonvulsant drug authorized by the FDA to cure many conditions. It is utilized to regulate control seizures, to cure nerve pain that can take place subsequent to having shingles and to cure a condition known as restless leg syndrome. Further to these FDA-consented uses, doctors may often advise gabapentin off-label drug use.

Gabapentin is FDA consented as Neurontin to cure restricted seizures in grown-ups and children with epilepsy. Partial seizures are convulsions that emanate from the solitary location in the brain. Neurontin is also consented to cure a kind of nerve pain known as postherpetic neuralgia, or PHN. PHN can take place subsequent to shingles, an infection from a similar virus, such as chickenpox, that engenders throbbing rash or blisters.

Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/gabapentin-market/request-for-sample

Growth Drivers:
Growing Cases of Neuropathic Ailments:
The market is notably impacted by growing cases of neuropathic ailment or epilepsy. It is extensively prescribed for handling neuropathic ailments associated with conditions such as diabetic neuropathy and postherpetic neuralgia. For instance, as per a March 2025 report by the DEA, USD 73.1 million in gabapentin prescriptions were spent in the US in 2024, rendering its ranking as seventh in the most commonly prescribed medicines nationally, driving up the gabapentin market demand.

Rising Usage in Off-Label Factor:
Beyond its approved indications, gabapentin is often used in several conditions involving insomnia, anxiety illnesses, and fibromyalgia. A February 2024 report by NIH expressed that amidst 172,607 patients, a contemporary off-label gabapentin prescription was linked with the reduction in opioid dosage for 67,016 patients. This finding highlights gabapentin's emerging role in pain management and opioid-sparing strategies.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/gabapentin-market/request-for-discount-pricing

Competitive Landscape:
There is intense competition in the market due to the presence of key players within the pharmaceutical sector, all focused on the production, distribution, and availability of generic formulations of gabapentin. Some of the prominent players operating in the market include:
• Amneal Pharmaceuticals, Inc.
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• Lupin Limited
• Mylan N.V.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.

Gabapentin Industry Developments:
• March 2024: Strides Pharma Science Limited (Strides) received approval from the U.S. Food and Drug Administration (USFDA) for its Gabapentin Tablets USP in 600 mg and 800 mg strengths.

• February 2023: Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals (USA) Inc., obtained tentative approval from the U.S. Food and Drug Administration (USFDA) for Gabapentin Tablets in 300 mg and 600 mg strengths, which are equivalent to the U.S. Reference Listed Drug Gralise Tablets.

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/gabapentin-market

Market Segmentation:
The gabapentin market segmentation is based on dosage, type, method, application, distribution channel, and region.

Based on dosage, the capsule segment held the largest market share in 2024 due to its ease and patient conformity.

Based on type, the generic segment dominated the market due to its formulation that offers an affordable option to the branded version.

Geographical Insights:
• North America
o US
o Canada

• Europe
o Germany
o France
o UK
o Italy
o Spain
o Netherlands
o Russia
o Rest of Europe

• Asia Pacific
o China
o Japan
o India
o Malaysia
o South Korea
o Indonesia
o Australia
o Vietnam
o Rest of Asia Pacific

• Middle East & Africa
o Saudi Arabia
o UAE
o Israel
o South Africa
o Rest of Middle East & Africa

• Latin America
o Mexico
o Brazil
o Argentina
• Rest of Latin America

Browse More Research Reports:
Neurothrombectomy Devices Market:
https://www.polarismarketresearch.com/industry-analysis/neurothrombectomy-devices-market

Microbiome Sequencing Services Market:
https://www.polarismarketresearch.com/industry-analysis/microbiome-sequencing-services-market

Capsule Endoscopy Market:
https://www.polarismarketresearch.com/industry-analysis/capsule-endoscopy-market

Biomarker Discovery Outsourcing Services Market:
https://www.polarismarketresearch.com/industry-analysis/biomarker-discovery-outsourcing-services-market

Elastography Imaging Market:
https://www.polarismarketresearch.com/industry-analysis/elastography-imaging-market

Single-Use Bioprocessing Connectors Market:
https://www.polarismarketresearch.com/industry-analysis/single-use-bioprocessing-connectors-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.